Thread by @ValueEducator

#SuvenPharma Q2 23 Concall Highlights

Like & Retweet for better reach !

1. De-growth in CRAMS and growth in specialty chemicals division.

2. Having better visibility now. Getting understanding from innovators that next year will be a normal year

3. 3. Suven pharma business should be looked at Year on Year and not qtr to qtr due to change in product mix and CRAMS orders can have Qtr to Qtr Volatility

4. For complete year EBITDA margins guidance of 40% + is intact

5. This qtr revenues from pharma was lower compared to agro chemicals but it will normalize over the next qtrs.

6. In this qtr Very small revenue from the covid drug. From next qtr it should come. It will be one off order

7. Innovators will be starting more projects so visibility will be better. They are Focusing on regular molecules after covid

8. China +1 is more for generics compared to innovative CRAMS

9. Looking for opportunities for long term wealth creation for shareholders.

10. CDMO pharma has 8 molecules which are commercial including covid molecule (Paxlovid) . Out of this 8, 2 are small products.

11. Moving products from one unit to another takes a couple of years (Vizag Unit). There are 3 regular customers who have taken validation batches,

it will take 6-9 months for validation.

12. Currently getting sales from 2 molecules in the agro chem segment. 3rd and 4th molecule sales will come after the end of 2024.

13. 2nd half looks better Pharma CRAMS and speciality chemicals. From initial guidance of -5% to flat current guidance is 2 to 5% growth. (Last year had covid related revenue - High Base)

14. No updates on new CEO, difficult to get right candidate

15. From casper pharma - Filled 4 ANDAs. 1 Product is launched which is of very small value. Will be filling 6-8 ANDAs in the next 6-8 months. Revenue generation will happen from FY 24

16. In pharma CDMO manufacturer gets passing on of the prices only once while

for agro chemicals division there can be in between passing-on depending on cost increase.